
Moderna’s work on a vaccine for coronavirus has made its founders into paper billionaires. Gilead Sciences has added $10 billion to its market value since the start of 2020. And a rising tide of Covid-19 speculation has sent one major biotech index to its all-time high.
But Sinovac, a Beijing-headquartered company with a coronavirus vaccine already in human trials, has been entirely left out. Thanks to a yearslong battle for corporate control — involving a secret coup, a poison pill, and an office raid — trading of Sinovac’s shares has been halted since early 2019, making for Nasdaq’s longest ongoing suspension.
What is it?
STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.
What's included?
- Daily reporting and analysis
- The most comprehensive industry coverage from a powerhouse team of reporters
- Subscriber-only newsletters
- Daily newsletters to brief you on the most important industry news of the day
- STAT+ Conversations
- Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
- Exclusive industry events
- Premium access to subscriber-only networking events around the country
- The best reporters in the industry
- The most trusted and well-connected newsroom in the health care industry
- And much more
- Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
Ok. It´s realy necessary?
why do I need to pay?